For pharmaceutical manufacturers, wholesale distributors, repackagers, third-party logistics providers, and dispensers, the Drug Supply Chain Security Act (DSCSA) has fundamentally changed how products move through the supply chain. Most organizations have invested significant time and resources into ensuring they only ship prescription drugs to Authorized Trading Partners, recognizing that failing to do so can expose the business to regulatory enforcement, product diversion, and patient safety concerns.
However, there is another side of the transaction that often receives far less attention: Who are you receiving product from?
Many companies have built robust procedures for validating customers before product leaves their facilities, yet they assume that suppliers, manufacturers, wholesalers, and other upstream trading partners have already completed their own compliance obligations. That assumption can create a significant regulatory blind spot.
Under the DSCSA, your responsibility does not end when you verify the legitimacy of your customers. You are also responsible for ensuring that every organization supplying prescription drug products to your business qualifies as an Authorized Trading Partner. If your organization accepts product from an entity that lacks the appropriate licenses, registrations, or credentials, the consequences can extend far beyond a simple compliance finding.
Compliance Is a Two-Way Responsibility
The pharmaceutical supply chain is only as strong as its weakest participant. Every transaction involves both a sender and a receiver, and both organizations share responsibility for maintaining the integrity of the supply chain.
Unfortunately, many compliance programs remain heavily focused on outbound transactions. Customer onboarding procedures frequently include extensive license reviews, DEA verification, and internal approval workflows before product is shipped. Incoming suppliers, on the other hand, are often approved based on limited documentation or outdated records that may no longer reflect their current regulatory status.
State licenses expire. DEA registrations change. FDA Establishment Registrations are updated. Authorized representatives leave organizations. Companies merge, relocate, or change ownership. Any of these changes can affect whether a trading partner continues to meet DSCSA requirements.
Without an ongoing verification process, organizations may unknowingly purchase prescription drug products from entities that are no longer properly authorized to participate in the pharmaceutical supply chain.
The Cost of Getting It Wrong
The risks associated with inadequate trading partner verification extend well beyond operational inconvenience.
Regulatory agencies continue to increase scrutiny of pharmaceutical supply chain compliance, particularly as DSCSA requirements continue to mature. During inspections, investigators may review how an organization verifies both its customers and its suppliers. If compliance procedures only address one side of the transaction, regulators may conclude that the company’s Authorized Trading Partner program is incomplete.
The result can include warning letters, disciplinary actions, financial penalties, corrective action requirements, increased inspection activity, and reputational damage. Even more concerning, receiving product from an unauthorized source increases the possibility that illegitimate or suspect products could enter your inventory, creating additional obligations under DSCSA and increasing risk to patients.
Organizations that treat trading partner verification as a one-directional process are exposing themselves to unnecessary compliance risk.
Manual Verification Is No Longer Enough
Many organizations still rely on spreadsheets, periodic reviews, or copies of licenses collected during onboarding. While these methods may have been sufficient years ago, today’s regulatory environment requires greater confidence.
Licenses can change overnight. Registrations can expire. Regulatory requirements differ from state to state and one mistake can put your trading partners’ license at risk, which puts you at risk.
Maintaining accurate trading partner records requires continuous monitoring across multiple regulatory agencies and licensing authorities. For organizations managing hundreds or even thousands of supplier relationships, performing this work internally can become a significant operational burden while still leaving room for human error.
The question is no longer whether trading partner verification should occur. The question is whether the process is comprehensive enough to withstand regulatory scrutiny.
Building Confidence Through Independent Verification
A mature DSCSA compliance program should provide confidence that every trading partner, whether sending or receiving product, has been independently verified using current regulatory information.
That is exactly why we developed ToVerify.
ToVerify provides comprehensive trading partner verification services designed specifically for pharmaceutical companies navigating DSCSA compliance. Rather than relying solely on static databases or self-reported information, our specialists perform Human Intelligence driven verification of the credentials that matter most, including state pharmaceutical licenses, DEA registrations, controlled substance licenses, FDA Drug Establishment Registrations, REMS enrollment where applicable, and pharmacist credentials.
By validating both inbound and outbound trading partners, organizations gain greater confidence that every transaction supports DSCSA compliance while reducing regulatory risk across the entire supply chain.
Compliance Should Never Be One-Sided
The safest pharmaceutical supply chains are built on complete visibility. Knowing who you ship to is essential, but knowing who you purchase from is equally important.
Organizations that verify only one side of the transaction leave themselves vulnerable to unnecessary compliance gaps that may not become apparent until an inspection, audit, or enforcement action occurs.
As regulatory expectations continue to evolve, businesses should evaluate whether their trading partner verification process truly addresses both ends of every transaction.
If your organization is looking to strengthen its DSCSA compliance, improve Authorized Trading Partner verification, reduce pharmaceutical supply chain risk, and ensure compliance with federal and state regulatory requirements, the team at State License Servicing can help.
Contact our team today to learn how ToVerify can independently verify your trading partners on both sides of every transaction, helping your organization build a stronger, more defensible DSCSA compliance program.